You wanted to release ZyCoV-D on Gandhi Jayanti. Was it delayed because of pricing issues?
Our original plan was to release it in October. Now we are waiting for the pricing approval. It is more complicated because there are three doses plus the injector plus the adapters. We hope to clear all that by this week and launch it as soon as it is done. It will be competitively priced. Our pricing is based on the technology, scale, capacity and procurement. There are a lot of advantages to this vaccine, and not only for today. It is a platform for the future.
Tell us about plasmid DNA, the technology behind world's first such vaccine.
This vaccine is focused on the virus’s spike protein. When administered in a human body, the ZyCoV-D will produce the spike protein of the SARSCoV-2 virus. There has been great interest in this technology because of its ability to elicit both humoral immune responses (relating to immune responses involving antibodies in body fluids) and cellular immune responses (antibodies in cells) and in showing relevant advantages regarding producibility, stability and storage.
The good part about this is that the vaccine constructs, which are generated quickly to deal with mutations in the virus, are non-replicating and there is no vector-based immunity built because we don’t use anything other than the spike protein. So there are no adjuvants (an ingredient used to create a stronger immune response) and no infectious vectors. All of it makes the administration of the vaccine easier. [The side effects, too, have been the lowest].
Esta historia es de la edición October 17, 2021 de THE WEEK.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición October 17, 2021 de THE WEEK.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
What Will It Take To Clean Up Delhi Air?
IT IS ASKED, year after year, why Delhi’s air remains unbreathable despite several interventions to reduce pollution.
Trump and the crisis of liberalism
Although Donald Trump's election to a non-consecutive second term to the US presidency is not unprecedented—Grover Cleveland had done it in 1893—it is nevertheless a watershed moment.
Men eye the woman's purse
A couple of months ago, I chanced upon a young 20-something man at my gym walking out with a women’s sling bag.
When trees hold hands
A filmmaker explores the human-nature connect through the living root bridges
Ms Gee & Gen Z
The vibrant Anuja Chauhan and her daughter Nayantara on the generational gap in romance writing
Vikram Seth-a suitable man
Our golden boy of literature was the star attraction at the recent Shillong Literary Festival in mysterious Meghalaya.
Superman bites the dust
When my granddaughter Kim was about three, I often took her to play in a nearby park.
OLD MAN AND THE SEA
Meet G. Govinda Menon, the 102-year-old engineer who had a key role in surveying the Vizhinjam coast in the 1940s, assessing its potential for an international port
Managing volatility: smarter equity choices in uncertain markets
THE INDIAN STOCK MARKET has delivered a strong 11 per cent CAGR over the past decade, with positive returns for eight straight years.
Investing in actively managed low-volatility portfolios keeps risks at bay
AFTER A ROARING bull market over the past year, equity markets in the recent months have gone into a correction mode as FIIs go on a selling spree. Volatility has risen and investment returns are hurt.